The global antinuclear antibody (ANA) test market size is likely to be USD 1,613.5 million in 2021 and is estimated to witness a CAGR of 12.85% during the forecast period. Growth in global incidence of autoimmune diseases is a key driver for the growth of the global Antinuclear Antibody (ANA) test market. Additionally, growth in population and increase in healthcare spending and rise in the number of individuals who are covered under different medical insurance are some of the other drivers propelling the market growth. Nevertheless, strict regulations related with the approval of manufacturing medical devices and execution of excise duty on import and export of medical devices in the U.S. are projected to restrain the global market growth.

By Product

Based on product, the market is segmented into systems, reagents & assay kits, and software & services. In 2021, the reagents & assay kits segment accounted for a substantial revenue share and is projected to grow with a lucrative CAGR during the forecast period. This is attributed to high adoption rate of this product segment in research and clinical settings worldwide. Software & services segment is projected to grow at a profitable CAGR during the forecast period. This is attributed to the rising penetration of healthcare IT in the healthcare structure and increase in the need to handle and permit prompt access to all patients’ related data.

By Technique

Based on technique, the market is segmented as multiplex assay, ELISA, and immunofluorescence assay. In 2021, the immunofluorescence assay segment accounted for a substantial revenue share and is anticipated to grow with a lucrative CAGR during the forecast period. This can be attributed to the high rate of adoption as this technique helps in the identification of patterns that indicate the related autoantibodies and underlying diseases such as speckled, nucleolar, and homogenous worldwide. ELISA segment is projected to grow at a profitable CAGR during the forecast period. This is attributed to the fact that these types of tests can easily be automated and do not require a high level of operative skill to perform the test.

By Application

Based on application, the market is categorized into sjogren’s syndrome, rheumatoid arthritis, scleroderma, systemic lupus erythematosus, and others. In 2021, the rheumatoid arthritis segment accounted for a substantial revenue share and is expected to grow with a lucrative CAGR during the forecast period. This is due to the rising incidence of this disease worldwide. The systemic lupus erythematosus segment is anticipated to grow at a profitable CAGR during the forecast period due to the rise in awareness along with the various government initiatives and increasing number of tests.

By End User

Based on end user, the market is categorized into clinical laboratories, hospitals, physician office laboratories, and others. In 2021, the hospitals segment accounted for a substantial revenue share and is anticipated to gow with a lucrative CAGR during the forecast period. This is due to the fact that increasing number of diagnostic investigations are implemented in hospitals, mostly because of easy access worldwide. The physician office laboratories segment is anticipated to grow at a profitable CAGR during the forecast period due to the benefits of expanded and vital role of physicians in the healthcare delivery system.

Regional Insights

In 2021, North America held highest revenue share in the global market and is likely to maintain its dominance during the forecast period. This is attributed to the large number of healthcare facilities in the region, increase in the share of healthcare expenditure in the per capita income, availability pf trained professionals for proper usage of the equipment, and accessibility of technologically advanced products in the region. Asia Pacific market is projected to grow at the fastest CAGR over the forecast period owing to the less stringent regulations, growing government and corporate investment in healthcare sector, increasing travel tourism in the developing economies, and growth in aged population in the region.

Competitor Insights

Some of the key players in the antinuclear antibody (ANA) test market are Alere Inc. (U.S.); Bio-Rad Laboratories, Inc. (U.S.); ERBA Diagnostics, Inc. (U.S.); Trinity Biotech plc (Ireland); Thermo Fisher Scientific, Inc. (U.S.); Antibodies, Inc. (U.S.); EUROIMMUN AG (Germany); Immuno Concepts (U.S.); Inova Diagnostics (U.S.); and Zeus Scientific, Inc. (U.S.). The leading players operating in the antinuclear antibody (ANA) test industry are adopting various strategies including R&D investments, adaption of advanced techniques, new technology launches, mergers & acquisitions, and regional expansions to capture a maximum revenue share.

This exhaustive research report focuses on market size and forecast at global, segmental, regional and country level along with key market trends and dynamics from 2021 to 2029. The antinuclear antibody (ANA) test market report is categorized into the following segments and subsegments:

Antinuclear Antibody (ANA) Test Market, By Product (Revenue, USD Million, 2021 – 2029)

Antinuclear Antibody (ANA) Test Market, By Technique (Revenue, USD Million, 2021 – 2029)

Antinuclear Antibody (ANA) Test Market, By Application (Revenue, USD Million, 2021 – 2029)

Antinuclear Antibody (ANA) Test Market, By End User (Revenue, USD Million, 2021 – 2029)

Antinuclear Antibody (ANA) Test Market, By Region (Revenue, USD Million, 2021 – 2029)

Scope of Antinuclear Antibody (ANA) Test Market Report:

Key Parameters	Details
Base Year	2021
Forecast Period	2022-2029
Study Coverage	Global and regional market size and revenue forecast Segment market size and revenue forecast at global, regional, and country level Competitive landscape (company share analysis, company profiles, recent development, competitive map analysis) Conclusion and recommendations
Qualitative Analysis	Market drivers Market restraints Market opportunities Recent market trends Market challenges Porter’s Five Forces analysis PEST analysis Value-chain analysis COVID-19 impact analysis
Regional Market Scope	North America (U.S. and Canada) Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe) Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC) Latin America (Brazil, Mexico, Argentina, Rest of LATAM) MEA (South Africa, GCC, Rest of MEA)
Company Profiles	Exhaustive profiles of top 15 players 50+ other major players listing
15% Free Customization Available	You can customize the study scope to meet your exact requirement. Click here for more details